Inlif Limited announces pricing of $3.75 million registered direct offering
- Inlif Limited priced a $3.75 million registered direct offering
- Sale includes 435,000 Class A Ordinary Shares at $1.60 per unit
- Offering features Series A, B, and C warrants with specific reset terms
- Transaction expected to close on or about October 20, 2026
*this image is generated using AI for illustrative purposes only.
Inlif Limited has announced the pricing of its registered direct offering to raise approximately $3.75 million in gross proceeds. The transaction involves securities purchase agreements with institutional investors for Class A Ordinary Shares and various warrant series.
The company, which specializes in injection molding machine-dedicated manipulator arms, entered into agreements for the sale of 435,000 Class A Ordinary Shares with a par value of $0.0001 per share. The offering also includes pre-funded warrants to purchase up to 1,908,750 Ordinary Shares.
Offering Structure and Warrants
The offering includes several types of warrants designed to provide additional equity potential to investors:
- Pre-funded warrants to purchase up to 1,908,750 Ordinary Shares
- Series A warrants to initially purchase up to 2,343,750 Ordinary Shares
- Series B warrants to initially purchase up to 2,343,750 units
- Series C warrants for a number of Ordinary Shares determined by their terms
Each unit sold consists of one Ordinary Share or one Pre-Funded Warrant, accompanied by one Series A Warrant, one Series B Warrant, and one Series C Warrant.
Pricing Details
The combined purchase price is set at $1.60 per Ordinary Share and accompanying Ordinary Warrants. For Pre-Funded Warrants, the price is $1.5999, reflecting the deduction of the $0.0001 exercise price from the total share price.
| Instrument | Quantity | Price per Unit |
|---|---|---|
| Class A Ordinary Shares | 435,000 | $1.60 |
| Pre-Funded Warrants | Up to 1,908,750 | $1.5999 |
| Series A Warrants | Up to 2,343,750 | Included |
| Series B Warrants | Up to 2,343,750 units | Included |
The aggregate gross proceeds are expected to be approximately $3.75 million, prior to deducting placement agent fees, legal fees, administrative costs, and other offering-related expenses.
Warrant Terms and Closing
The Series A Warrants are immediately exercisable at $1.60 per Ordinary Share and expire five years after closing. The Series B Warrants are immediately exercisable at $1.60 per unit and expire 60 days after issuance. Both warrant series are subject to a one-time downward exercise price reset on the twentieth trading day after closing.
The Series C Warrants are exercisable at $0.0001 per share for additional Ordinary Shares determined by a price-based adjustment over the first ten trading days beginning on issuance. The transaction is expected to close on or about October 20, 2026, subject to customary closing conditions.
Maxim Group LLC is acting as the sole placement agent for the offering. Ortoli Rosenstadt LLP is acting as U.S. securities counsel to the Company, and Pryor Cashman LLP is acting as U.S. securities counsel to the placement agent.
How will the dilution from the potential exercise of over 6.5 million warrant shares impact Inlif's future earnings per share and voting control?
What specific capital expenditure projects or R&D initiatives will the net proceeds from this offering primarily fund to support growth?
Given the downward reset provisions on Series A and B warrants, what is the risk of further dilution if the stock price declines post-closing?
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
